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Background: MicroRNA-222 (miR-222) has been shown to play a potential oncogenic role in bladder cancer. The
aim of this study was to evaluate the expression of miR-222 in bladder cancer and its potential relevance to
clinicopathological characteristics and patient survival.
Methods: Surgical specimens of cancer tissue and adjacent normal tissue were obtained from 97 patients with
bladder cancer. The relative expression levels of miR-222 in the cancer and the normal adjacent tissue were
measured by quantitative reverse-transcriptase PCR. We analyzed their correlation with clinicopathological
parameters and prognostic value.
Results: The expression level of miR-222 was significantly higher in tumor tissues than in corresponding non-cancerous
tissues (5.46 ± 1.45 versus 1.92 ± 0.65, P < 0.0001), and a high expression of miR-222 was found to be significantly
associated with tumor grade (P = 0.003) and tumor stage (P = 0.005). The miR-222 expression level was classified as high
or low in relation to the median value (cutoff value = 5.15). Kaplan-Meier analysis showed that patients with higher levels
of miR-222 had significantly poorer survival than those with lower expression of this miRNA in patients, with a 5-year
overall survival of 29.53% and 52.75%, respectively (P = 0.0034). In the multivariate Cox proportional hazards
analysis, which included miR-222 level, tumor grade, tumor stage, and tumor number, high miR-222 expression
was independently associated with poor survival (P < 0.001; hazard ratio 6.17; 95% CI 2.33 to 10.39).
Conclusion: miR-222 overexpression is involved in the poor prognosis of bladder cancer and can be used as a
biomarker for selection of cases requiring special attention.
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Bladder cancer is the thirteenth leading cause of cancer
death worldwide [1]. The age-adjusted incidence rate
was 20.8 per 100,000 men and women per year, and the
age-adjusted death rate was 4.4 per 100,000 men and
women per year from 2006 to 2010. The incidence of
bladder cancer increases with age, peaking between 50
and 70 years, and the disease is approximately three
times more common in males than in females [2].
miRNAs have been identified as signatures associated
with diagnosis, staging, progression, prognosis, and re-
sponse to treatment in human cancer [3-5]. Mature
miRNAs are small (20 to 21 nucleotides in length) en-
dogenous non-coding RNAs that regulate the expression* Correspondence: dr_zhangdongqing@126.com
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unless otherwise stated.of target genes at the post-transcription level through deg-
radation of transcripts and inhibition of translation by
mainly binding to the 3’-UTR of target mRNA [6]. The
functions of miRNA have been shown to be involved in
various critically important physiological processes such
as cell proliferation, cell division, cell differentiation, cell
apoptosis, tumorigenesis, hematopoiesis, and patterning
of the nervous system [7,8].
microRNA-222 (miR-222) belongs to the miR-221/222
family, which was encoded in tandem on chromosome X.
Recently, accumulating evidence has demonstrated that
miR-222 plays a crucial role in cancer cell proliferation
[9], and overexpression of miR-222 has been found in se-
veral types of cancers such as breast cancer [10], colorectal
carcinoma [11], glioblastoma [12], ovarian cancer [13],
prostate cancer [14], and pancreatic cancer [15]. However,
the expression of miR-222 in bladder cancer and itsLtd. This is an Open Access article distributed under the terms of the Creative
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present study is to evaluate the clinical significance of
miR-222. The expression level of the miR-222 was mea-
sured in both adjacent normal tissue and cancerous tissue.
Furthermore, the correlation between the expression level
of miR-222 and clinicopathological characters was ana-
lyzed. In addition, the influence of miR-222 on the prog-
nosis of bladder cancer patients was estimated.
Methods
Study cohort and samples
This study was approved by the Research Ethics Com-
mittee of Qilu Hospital. Written informed consent was
obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical
and legal standards. Clinicopathological data including
age, gender, number of tumors, pathological stage, and
tumor grade were collected. Patient characteristics are
shown in Table 1. None of the patients recruited in this
study had undergone preoperative chemotherapy or
radiotherapy. For each case, the diagnosis and the histo-
logic grade were confirmed by two pathologists. The
duration of follow-up was calculated from the date of
surgery to death or last follow-up, and patients were
excluded if they had incomplete medical records or in-
adequate follow-up. For quantitative reverse-transciptase
polymerase chain reaction (qRT-PCR), 97 pairs of fresh
bladder cancer and matched adjacent normal tissue
specimens were collected from patients who underwent
surgery between May 2008 and August 2012 in Qilu
Hospital. The fresh tissue specimens were collected andTable 1 Association between microRNA-222 expression
and different clinicopathological features of bladder
cancer
Variable n Relative microRNA-222 level P value
Gender
Female 46 5.33 ± 1.22
Male 51 5.56 ± 1.53 0.65
Age (years)
<60 59 5.01 ± 1.34
≥60 38 5.79 ± 1.49 0.17
Number of tumors
Single 73 4.97 ± 1.23
Multiple 24 5.88 ± 1.92 0.09
Stage
Ta-T1 82 4.19 ± 1.32
≥T2 15 8.11 ± 1.46 0.005
Grade
G1/2 39 3.42 ± 1.27
G3 58 7.91 ± 1.57 0.003immediately placed in liquid nitrogen and then stored
at -80°C until the isolation of RNA.
RNA isolation and qRT-PCR
Total RNA was isolated from frozen specimens by hom-
ogenizing tissue in Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
The purity and concentration of RNA were determined
using a NanoDrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). The differentially ex-
pressed amount of the miR-222 was validated in triplicate
by qRT-PCR. Briefly, 2 μg RNA was added to the RT reac-
tion; the cDNA then served as the template for ampli-
fication of PCR with sequence-specific primers (Sangon
Biotech, Shanghai, China) using the SYBR PrimeScript
miRNA RT-PCR kit (Takara Biotechnology Co. Ltd,
Dalian, China) on the 7500 Real-Time PCR systems
(Applied Biosystems, Carlsbad, CA, USA). The PCR cycling
profile was denatured at 95°C for 30 seconds, followed by
40 cycles of annealing at 95°C for 5 seconds, and extension
at 60°C for 34 seconds. Small nucleolar RNA U6 was used
as an internal standard for normalization. The cycle thresh-
old (CT) value was calculated. The 2
-ΔCT (ΔCT =CTmiR222-
CTU6 RNA) method was used to quantify the relative
amount of miR-222. Real-time PCR primers used were:
miR-222 - (forward) 5'-CGCAGCTACATCTGGCTAC




The comparison of the expression level of miR-222 bet-
ween bladder cancer tissue and adjacent normal tissue
was performed using the two-sample Student’s t test.
The correlation between the expression of miR-222 and
clinicopathological characters was assessed with the
two-sample Student’s t test. The overall survival was an-
alyzed by log-rank test, and survival curves were plotted
according to Kaplan–Meier. Univariate Cox regression
was performed on each clinical covariate to examine its
influence on patient survival. Final multivariate models
were based on step-wise addition. A Wald statistic of
P < 0.05 was used as the criterion for inclusion in final
multivariate models. All tests were two tailed and results
with P < 0.05 were considered statistically significant.
Statistical analyses were performed using SPSS 13.0 soft-
ware (Chicago, IL, USA) and GraphPad Prism 5 (Graph-
Pad Software Inc., CA, USA).
Results
Expression of miR-222 in bladder cancer tissues by
qRT-PCR
We examined miR-222 protein expression in 97 pairs
of bladder cancer tissues and the corresponding non-
Figure 1 Comparison of microRNA-222 expression levels between
bladder cancer tissue and adjacent normal tissue. Analysis using
the two sample Student’s t test showed that the relative expression
levels of microRNA-222 (miR-222) in the bladder cancer tissue were
significantly higher than those in adjacent normal tissue (P < 0.0001).
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expression level of miR222 was significantly higher in
tumor tissues than in corresponding non-cancerous tis-
sues (5.46 ± 1.45 versus 1.92 ± 0.65, P < 0.0001).
Correlation of miR-222 expression with clinicopathological
characteristics
The relationship between miR-222 expression and dif-
ferent clinicopathological factors is shown in Table 1. In-
creased miR-222 expression in bladder cancer was found
to be significantly associated with tumor grade (Ta-T1
versus ≥ T2: 4.19 ± 1.32 versus 8.11 ± 1.46, P = 0.003) and
tumor stage (G1/2 versus G3: 3.42 ± 1.27 versus 7.91 ±
1.57, P = 0.005). However, no significant correlation wasFigure 2 Kaplan–Meier survival curves in relation to microRNA-222 le
with high microRNA-222 (miR-222) level was significantly lower than that oobserved between miR-222 expression and other clinico-
pathologic variables such as age, gender, tumor size, and
number of tumors (all P > 0.05).
Relationship between miR-222 expression and survival of
bladder cancer patients
The miR-222 expression level was classified as high or
low in relation to the median value (cutoff value = 5.15).
To evaluate whether miR-222 expression can predict
bladder cancer prognosis, we next performed survival
analysis. Kaplan-Meier analysis showed that patients
with higher levels of miR-222 had significantly poorer
survival than those with lower expression of this miRNA
in patients, with a 5-year overall survival of 29.53%
and 52.75%, respectively (P = 0.0034; Figure 2). Because
the survival of G3T3 bladder cancer is much less than
G1/2Ta/1/2 bladder cancer (n = 21), we next performed
survival analysis for patients diagnosed with G3T3 blad-
der cancer. Kaplan-Meier analysis showed that patients
with higher levels of miR-222 had significantly poorer
survival than those with lower expression of this miRNA
in patients diagnosed with G3T3 bladder cancer, with a
5-year overall survival of 6.66% and 50.00%, respec-
tively (P = 0.039; Figure 3). A Cox proportional hazards
analysis was used to further evaluate the potential of
miR-222 expression as a prognostic biomarker. Univa-
riate survival analyses indicated that miR-222 expression,
tumor stage, and tumor grade were associated with
prognosis, while gender, age and tumor number were
not associated with prognosis. In the multivariate Cox
proportional hazards analysis, which included miR-222
level, tumor grade, tumor stage, and tumor number, high
miR-222 expression was independently associated withvel in 97 patients with bladder cancer. The survival rate of patients
f patients with low miR-222 level (log-rank test P = 0.0034).
Figure 3 Kaplan–Meier survival curves in relation to microRNA-222 level in 21 patients with T3G3 bladder cancer. The survival rate of
patients with high microRNA-222 (miR-222) level was significantly lower than that of patients with low miR-222 level (log-rank test P = 0.039).
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to 10.39; Table 2).
Discussion
Identification of miRNA molecular profiles associated
with the prognosis of patients with bladder cancer may
not only elucidate the underlying biological mechanisms
involved in the development or progression of the dis-
ease but also provide the opportunity to identify novel
targets for bladder cancer therapy. In 2009, Veerla and
colleagues found that the expression of miR-222 was ob-
viously upregulated in bladder cancer samples compared
with adjacent normal tissues [16]. Recently, Puerta-Gil
and colleagues found a significant correlation in quan-
titative levels of expression between the urinary sam-
ples and matching tumors for miR-222 (P = 0.008), and
qRT-PCR of miR-222 in urine could provide high accu-
racy for bladder cancer diagnosis [17]. Furthermore,
they found that miR-222 expression was significantlyTable 2 Multivariate Cox's hazards model analysis for
prognostic factors










Stage (≥T2 versus Ta-T1) 2.98 (1.91-5.69) 0.003
Grade (G3 versus G1/G2) 3.01 (1.78-8.11) 0.002
Number of tumors
(multiple versus single)
1.92 (0.92-4.91) 0.11correlated with increasing tumor grade (P = 0.017), tumor
size (P = 0.005), presence of carcinoma in situ (P = 0.035),
and clinical outcome endpoints (recurrence, P = 0.006;
progression, P = 0.003; disease-specific survival, P = 0.034;
and overall survival, P = 0.023). However, the expression
level of miR-222 and its clinical significance in Asian
patients with bladder cancer remains unclear. In the
present study, 97 Chinese patients diagnosed with bladder
cancer were included. We found that the expression level
of miR-222 was significantly higher in tumor tissues than
in corresponding non-cancerous tissues. Furthermore,
miR-222 expression was proven to be associated with
tumor stage and tumor grade, suggesting that miR-222
might be involved in the carcinogenesis and metastasis of
bladder cancer. More importantly, we proved that patients
with a high expression of miR-222 tended to have shorter
survival than patients with lower levels, indicating that a
high miR-222 level is a marker of poor prognosis for pa-
tients with bladder cancer.
Overexpression of miR-222 has been observed in se-
veral types of cancers such as breast cancer [10], colo-
rectal carcinoma [11], glioblastoma [12], ovarian cancer
[13], prostate cancer [14], and pancreatic cancer [15],
suggesting its important role in tumorigenesis. Lee and
colleagues [15] found that the tissue expression levels of
miR-222 were significantly upregulated in pancreatic
cancer samples compared with those in adjacent normal
tissues (P = 0.00001). Multivariate analysis with Cox’s
proportional hazards model confirmed that the miR-222
high expression level was an independent predictor of
poor prognosis for the patients with pancreatic cancer.
Furthermore, they found that overexpression of tissue
miR-222 strongly related to the expression level of Ki67,
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and colleagues found that miR-221/222 targets adiponec-
tin receptor 1 to promote the epithelial-to-mesenchymal
transition in breast cancer [10]. Sun and colleagues [13]
found that miR-222 expression was upregulated in ovarian
cancer. Furthermore, their results also provided functional
evidence concerning the possible role of miR-222 in ovar-
ian cancer, as it was demonstrated that miR-222 upregula-
tion is able to induce an enhancement of ovarian cancer
cell proliferation potential, possibly by downregulating its
target, P27Kip1. A bioinformatic analysis showed that the
3'-UTR of the P27Kip1 mRNA contained the highly con-
served putative miR-222 binding site [13]. Quintavalle and
colleagues found that miR-222 regulates glioma tumori-
genesis at least in part through the control of PTPμ pro-
tein expression [12].
In this study, we confirmed the clinical importance of
miR-222 expression by showing its association with un-
favorable clinicopathological features and poor survival.
However, the precise molecular mechanisms behind the
altered expression of miR-222 in bladder cancer are
unclear. Recently, Calderaro and colleagues found that
miR-222 was involved in the PI3K/AKT pathway, which
is considered to play a major role in bladder carci-
nogenesis [19]. Additional studies to investigate the
molecular mechanisms of both the cause and the effects
of altered expression of miR-222 in the development
and/or progression of bladder cancer are essential.
Conclusion
In conclusion, our results show that miR-222 was over-
expressed in bladder cancer, and its high expression indi-
cated an association with poor prognostic factors and
poor survival. To clarify the role of miR-222, as well as its
use as a biomarker and in targeting therapy, large world-
wide population-based studies with a standard definition
of miR-222 expression level are necessary.
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